Gilead Sciences will distribute remdesivir as a coronavirus drug at $2,340 per patient and the U.S. is expected to be the first country to get most of the company's supply.Original Article
You may also like
Gone in a Puff of Smoke? FDA’s Proposed Rule on...
FDA Appears to Be Granting Zombie Rare Pediatric...
HPM’s Larry Houck Presenting at WCF Opioid and...
Get Up To Speed on Medicare Inflation Rebates: HPM...
Into the Ashtray: FDA’s Previous Proposal to Ban...
Small Change: FDA’s Final Predetermined Change...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.